BioNJ’s 4th Annual CEO Summit, scheduled for Friday, September 23, 2016 at the Bridgewater Marriott, is expected to bring together more than 300 life sciences C-suite leaders and their teams — representing a wide breadth of companies from early to late stage, as well as public, private, revenue and pre-revenue enterprises. The full-day program will deliver valuable perspectives from industry leaders on how to navigate the dynamic landscape of bringing a product to market.
“We’re thrilled to have assembled such an outstanding roster of key stakeholders at the forefront of this vital conversation impacting patient access to medical innovation,” said Debbie Hart, President and CEO, BioNJ. “With insights from McKinsey & Company, the agenda will dive into the critical considerations and factors driving today’s increasingly complex journey to market, with a focus on how to achieve successful outcomes, from raising capital to M&A to market launch.”
The full-day schedule includes a luncheon Keynote presentation by James Greenwood, President and CEO of BIO, on how the results of the impending presidential election may impact the industry, as well as a robust syllabus of plenary sessions, including:
“Keeping to our theme, Take It to the Top, we have once again set the bar very high with an important program highlighting industry leaders, timely topics and productive networking events,” said Hart.Related Articles: